MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: INKT) | Delayed: 10.71 +0.65 (6.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.06 | 52 Week High | $ | |||
| Open | $10.64 | 52 Week Low | $ | |||
| Day High | $11.68 | P/E | N/A | |||
| Day Low | $10.18 | EPS | $ | |||
| Volume | 29,409 | |||||
